MedTrace Logo

Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency

NCT02273349 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-05-02

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety and effectiveness of the RePneu Lung Volume Reduction Coil (LVRC) in patients with Alpha-1-Antitrypsin deficiency (AATD) caused emphysema. The hypothesis is that emphysema in AATD patients shows similar tissue destruction profile was well as symptoms and thus will respond favorably to LVRC treatment, demonstrating improvement in lung function, exercise capacity, and quality of life relative to their baseline status.

Conditions

  • Alpha-1-Antitrypsin Deficiency
  • Chronic Obstructive Lung Disease
  • Emphysema

Interventions

DEVICE

Lung Volume Reduction Coil (PneumrX Inc.)

Endoscopic Lung Volume Reduction

Sponsors & Collaborators

  • University Hospital, Saarland

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-08-31
Completion
2015-10-31

Countries

  • Denmark
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02273349 on ClinicalTrials.gov